New adaptive radiotherapy aims to shrink treatment margins for uterine cancers
NCT ID NCT05682950
First seen Jun 27, 2026 ยท Last updated Jun 27, 2026
Summary
This study tested a new type of radiation therapy that adjusts the treatment plan daily based on the patient's anatomy. It included 15 women with endometrial or cervical cancer who had surgery and needed radiation. The goal was to see if smaller treatment margins could be used safely, potentially reducing side effects while still covering the target area.
What this could mean
Our plain-language read of the trial. This is informational only โ not medical advice or a prediction.
- Active substance
- online adaptive radiotherapy
- What this could lead to
- If successful, this approach could reduce radiation side effects for women with endometrial or cervical cancer by using daily adaptive planning to shrink treatment margins.
- What could go wrong
- This is a small, early-phase study with only 15 participants, so results may not apply to all patients. The technique also requires more time and resources per session.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100730, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can an antiviral make radiation more effective against cervical cancer?
- What raises endometrial cancer risk in black women? a study digs in
- A One-Two punch against cervical cancer: testing plus vaccination in HIV-Positive women
- Can a Two-Antibody combo outsmart advanced cancer?
- Can immunotherapy plus hormones spare the womb in early endometrial cancer?